| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMRA1515161 |
| P698 | PubMed publication ID | 26886523 |
| P2093 | author name string | Andrew L Mammen | |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 664-669 | |
| P577 | publication date | 2016-02-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Statin-Associated Autoimmune Myopathy | |
| P478 | volume | 374 |
| Q33584194 | A Case of Statin-Associated Autoimmune Myopathy |
| Q41678852 | A severe myopathy case in aged patient treated with high statin dosage |
| Q47115222 | Aggressive and fatal statin-induced dermatomyositis: a case report |
| Q51206969 | Anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase necrotizing myopathy masquerading as a muscular dystrophy in a child. |
| Q36196309 | Anti-HMGCR antibodies in systemic sclerosis |
| Q48253771 | Anti-HMGCR autoantibodies in self-limiting statin-induced myopathy. |
| Q47248671 | Association between statin use and physical function among community-dwelling older Japanese adults |
| Q90728069 | Association of Statin Exposure With Histologically Confirmed Idiopathic Inflammatory Myositis in an Australian Population |
| Q89365586 | Atorvastatin-induced dermatomyositis |
| Q37613347 | Atorvastatin-induced necrotizing autoimmune myositis: An emerging dominant entity in patients with autoimmune myositis presenting with a pure polymyositis phenotype |
| Q52597638 | Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians? |
| Q90415641 | Autoantibodies in Myositis. How to Achieve a Comprehensive Strategy for Serological Testing |
| Q26744554 | Autoimmune Myopathies: Where Do We Stand? |
| Q37324573 | Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy |
| Q33633032 | Chromatin-modifying agents convert fibroblasts to OCT4+ and VEGFR-2+ capillary tube-forming cells |
| Q90164298 | Creatine as a Candidate to Prevent Statin Myopathy |
| Q92616166 | Detection of Anti-mitochondrial Antibodies Accompanied by Drug-induced Hepatic Injury due to Atorvastatin |
| Q53375302 | Editorial: A New Classification of Adult Autoimmune Myositis. |
| Q61814304 | Enduring Neuroprotective Effect of Subacute Neural Stem Cell Transplantation After Penetrating TBI |
| Q37653029 | Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy |
| Q61447185 | Formal comment on "Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease" |
| Q47320133 | HLAs: Key regulators of T-cell-mediated drug hypersensitivity. |
| Q48217656 | HMG CoA reductase inhibitor associated myositis and autoimmune hepatitis |
| Q39166726 | Histopathologic and Biochemical Evidence for Mitochondrial Disease Among 279 Patients with Severe Statin Myopathy |
| Q99403781 | Immune-Mediated Necrotizing Myopathy Initially Presenting as Erythema Nodosum |
| Q52628910 | Immune-Mediated Necrotizing Myopathy. |
| Q54114503 | Immune-mediated necrotising myopathy: a rare cause of hyperCKaemia. |
| Q58573177 | Induction of Osmolyte Pathways in Skeletal Muscle Inflammation: Novel Biomarkers for Myositis |
| Q89451120 | Invalidisierende Muskelschwäche |
| Q58362346 | Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017 |
| Q89751913 | Levetiracetam inhibits THP-1 monocyte chemotaxis and adhesion via the synaptic vesicle 2A |
| Q50062309 | Lipid-lowering agent-triggered dermatomyositis and polymyositis: a case series and literature review |
| Q50948932 | More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. |
| Q54978610 | Myopathy due to HMGCR antibodies in adult mimicking muscular dystrophy associated with cancer and statin exposure - narrative review of the literature - case report. |
| Q55482060 | Near-Fatal Statin-Associated Autoimmune Myositis. |
| Q59314534 | New Antilipid Drugs: Do the Known Benefits Justify the Expense? |
| Q55011566 | Nonadherence to statins: individualized intervention strategies outside the pill box. |
| Q90394916 | Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies |
| Q46162310 | PCSK9 Inhibitors for Statin Intolerance? |
| Q38948633 | Pathogenic role of anti-signal recognition protein and anti-3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. |
| Q38644316 | Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge |
| Q30400366 | Pharmacogenomics of off-target adverse drug reactions |
| Q41975807 | Point-Counterpoint: SLCO1B1 Genotyping for Statins |
| Q90733684 | Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies |
| Q55517453 | Rifaximin as a rare cause of rhabdomyolysis in cirrhosis. |
| Q89022021 | Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence |
| Q28074144 | Statin-Associated Muscle Adverse Events: Update for clinicians |
| Q96305510 | Statin-Induced Immune-Mediated Necrotizing Myopathy: An Increasingly Recognized Inflammatory Myopathy |
| Q92156926 | Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components |
| Q53123787 | Statin-associated autoimmune myopathy. |
| Q92501690 | Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients |
| Q52688656 | Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. |
| Q90290164 | Statin-induced myopathy: a case report |
| Q90086832 | Statin-induced necrotizing autoimmune myopathy: An uncommon complication of a commonly used medication |
| Q89456933 | Statin-induced necrotizing autoimmune myopathy: an extremely rare adverse effect from statin use |
| Q55312692 | Statins: pros and cons. |
| Q54248374 | Triggers of inflammatory myopathy: insights into pathogenesis. |
| Q58589752 | When Should a Patient with Statin-Induced Myopathy Be Re-challenged? A Case of Necrotizing Autoimmune Myopathy |
Search more.